PATENT CLAIM ANALYSIS

Application Number: 15773084
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "017600"]

Abstract:
This disclosure features combinations of NMDA modulators and atypical antipsychotics. The disclosure provides for example, methods of treating schizophrenia, bipolar disorder, and/or cognitive impairment disorder in a patient in need thereof, comprising administering e.g., rapastinel and an atypical antipsychotic.

Claim (Index 1):
A method of treating schizophrenia in a patient in need thereof, comprising administering to the patient:\n an atypical antipsychotic; and an NMDA modulator selected from the group consisting of rapastinel, (S)\u2014N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-((S)-1-((S)-2-amino-3-hydroxypropanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide, (S)\u2014N\u2014((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-1-((S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl) pyrrolidine-2-carbonyl) pyrrolidine-2-carboxamide, (S)\u2014N\u2014((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-1-((S)-1-((S)-2-amino-3-hydroxy-propanoyl)-pyrrolidine-2-carbonyl)-pyrrolidine-2-carboxamide, and N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-((S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl)-pyrrolidine-2-carbonyl)-2-benzylpyrrolidine-2-carboxamide.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 93.0
- Lexical Diversity: 1.31429
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15320155', '14770331', '15547776', '12829526', '15341275']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7426712224625794
- 35 USC 102 Novelty (BERT): 0.5024366840779225
- Combined Prediction Score: 0.7186477686241137
- Mean Citation Score: 213.488412
- Max Citation Score: 227.16086
- Similarity Product: 146.51734222364428

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test